85803-43-6

Basic information

• Product Name: S-BENZYL-L-CYSTEINOL
• Synonyms: S-BENZYL-L-CYSTEINOL;(R)-2-AMINO-3-(BENZYLTHIO)-1-PROPANOL;H-CYS(BZL)-OL;H-CYSTEINOL(BZL);L-CYSTEINOL(BZL);(R)-2-amino-3-(benzylthio)propan-1-ol;S-Benzyl-L-cysteinol 97%;H-L-Cys(Bzl)-ol
• CAS NO: 85803-43-6
• Molecular Formula: C₁₀H₁₅NOS
• Molecular Weight: 197.3
• Product Categories: Amino alcohols
• Mol File: 85803-43-6.mol
• Article Data: 5

Chemical Properties

• Melting Point: 42-46 °C(lit.)
• Boiling Point: 358°C at 760 mmHg
• Flash Point: >230 °F
• Appearance: /
• Density: 1.155g/cm³
• Vapor Pressure: 9.54E-06mmHg at 25°C
• Refractive Index: 1.595
• Storage Temp.: Store at 0°C
• PKA: 12.63±0.10(Predicted)
• CAS DataBase Reference: S-BENZYL-L-CYSTEINOL(CAS DataBase Reference)
• NIST Chemistry Reference: S-BENZYL-L-CYSTEINOL(85803-43-6)
• EPA Substance Registry System: S-BENZYL-L-CYSTEINOL(85803-43-6)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 85803-43-6(Hazardous Substances Data)

Usage

General Description

S-Benzyl-L-cysteinol is a chemical compound that belongs to the family of cysteine derivatives. It is an antioxidant and a chiral building block used in the synthesis of various pharmaceuticals and other organic compounds. S-BENZYL-L-CYSTEINOL has been studied for its potential use as a therapeutic agent for treating oxidative stress-related diseases and as an ingredient in cosmetic and personal care products. Additionally, S-benzyl-L-cysteinol has shown potential as a flavoring agent in food products and as a chiral auxiliary in asymmetric synthesis reactions. Overall, this chemical compound has a wide range of potential applications in various industries.

InChI:InChI=1/C10H15NOS/c11-10(6-12)8-13-7-9-4-2-1-3-5-9/h1-5,10,12H,6-8,11H2/t10-/m0/s1

Upstream product

• 52844-67-4 S-benzyl-L-cysteine ethyl ester hydrochloride 
• 22728-88-7 S-benzylcysteine methyl ester 
• 3054-01-1 S-benzyl-L-cysteine 
• 953-18-4 S-benzyl-L-cysteine ethyl ester 

Downstream Products

• 273401-71-1 (1-benzyloxymethyl-2-benzylsulfanyl-ethyl)-carbamic acid tert-butyl ester 
• 139428-96-9 N-tert-butoxycarbonyl-S-benzyl-(R)-cysteinol 
• 185146-21-8 (R)-1-Benzylsulfanylmethyl-2-(tert-butyl-dimethyl-silanyloxy)-ethylamine 
• 111904-35-9 (1'R)-2-fluoro-N-<1-(hydroxymethyl)-2-(benzylthio)-ethyl>benzamide 
• 916347-57-4 (2R)-3-(benzylthio)-2-{[(1R)-3-cyclopropyl-1-(4-fluorophenyl)-1-(trifluoromethyl)prop-2-yn-1-yl]amino}propan-1-ol 
• 916347-58-5 3-(benzylsulfonyl)-N-[(1R)-3-cyclopropyl-1-(4-fluorophenyl)-1-(trifluoromethyl)prop-2-yn-1-yl]-L-alanine 

Relevant articles and documents

TREATMENT OF H. PYLORI INFECTIONS USING MTAN INHIBITORS

Methods of treating infections due to Helicobacter pylori (H. pylori), in particular in subjects having a peptic ulcer, are disclosed where the methods comprise administering inhibitors of H. pylori MTAN (5'-methylthioadenosine nucleosidase) to the subject.

Aldehyde derivatives and their use as calpain inhibitors

Aldehyde derivatives with a specific calpain inhibiting activity and a platelet-aggregation inhibiting effect with formula (I) or formula (II): wherein R1 represents an aromatic hydrocarbon group, a heterocyclic group, or a group of-X-R3 in which X represents O,-S(O)m-(m = 0, 1, or 2), and R3 represents an aromatic hydrocarbon group, a heterocyclic group, or an alkyl group; Z represents R?-Y-or R?O-CH(R?)-in which Y represents a 3-to 7-membered nitrogen-containing saturated heterocyclic group, or a single cyclic saturated hydrocarbon group, R? represents an alkyl group, an alkenyl group, an alkynyl group, an acyl group, a sulfonyl group, an alkoxycarbonyl group, a carbamoyl group, or a thiocarbamoyl group, R? represents hydrogen, an alkyl group, or an aromatic hydrocarbon group, and R? represents an acyl group, a carbamoyl group, a thiocarbamoyl group, or an alkyl group; and n is an integer of 1 to 5. wherein R?, R?, R?, and R1? are defined in the specification.

Pyrimidinylpropenamides as antitumor agents. Analogues of the antibiotic sparsomycin

A series of pyrimidinylpropenamides 9 and their oxidation products 10 was prepared, as analogues of sparsomycin (1), for antitumor evaluation. Syntheses involved condensation of the appropriate amino alcohol 5 with acid 8. The resulting sulfides 9 were then oxidized with NaIO4 or H2O2 to sulfoxides 10. Activity was studied in lymphocytic leukemia P-388 and KB cell culture. With the exception of the n-decyl analogue, all of the deoxygenated compounds 9 were inactive regardless of the sterochemical form. In the sulfoxide series 10, those compounds prepared with an L configuration at the asymmetric carbon were also inactive. The completely racemic sulfoxides, on the other hand, displayed substantial antitumor activity (ILS=37-61% in P-388; ED50=1.2-2.4μg/ml in KB) suggesting that both the presence of a sulfoxide moiety and a D configuration at the chiral carbon atom were structural requirements for a positive antitumor response. There appeared to be a large tolerance for the group substituted at the sulfoxide moiety, however.